In August 2023, the Bulgarian Ministry of Health published a draft bill for amendment of the Law on Medicinal Products in the Human Medicine for public consultations. The proposed changes mark a shift towards greater transparency and regulatory control over the pharmaceutical value chain in Bulgaria. They target practices of parallel distributors which lead to shortages of key medicinal products.
Parallel distribution has emerged as one of the main factors shaping the pharmaceutical landscape in Bulgaria. The distribution of medicinal products freely across the single EU market offers patients a broader selection of medicines at competitive prices. However, parallel distribution is often identified as one of the reasons for the shortage of medicinal products in Bulgaria and the CEE&SEE region.
Draft bill for amendment of the Law on Medicinal Products in the Human Medicine includes the following key proposals:
- the introduction of similar obligations for parallel distributor as marketing authorization holders. These include informing the Bulgarian Drug Agency about the marketing date of the medicinal product in Bulgaria and providing a 3-month written notice before any (temporary or permanent) suspension of sales.
- adjustments to the formula for the calculation of medicine shortages and the introduction of an expedited administrative procedure for authorizing parallel imports during shortage periods.
- The inclusion of medicinal products, for which notifications of suspension of sales have been submitted, in a nation-wide export ban list. Additionally, medicinal products identified in the specific shortages list of the European Medicines Agency may also be subject to export bans if reimbursed locally.
The draft bill is currently pending submission and discussions before the Bulgarian Parliament.
In addition, the Commission for the Protection of Competition (CPC), the Bulgarian competition watchdog, launched advocacy proceedings over parallel export & import regime in November 2023. The focus of the debate is whether current legislative framework in Bulgaria complies with competition law and adequately deals with shortages issues. It is notable that the CPC will consider both regimes – for parallel exports and for parallel imports. Historically, the CPC has played a crucial role in the dynamics of the medicinal market, safeguarding the observation of the free movement of products in the single market and the efficiency of competition rules.
Life Science Bulletin: Upcoming changes to parallel distribution of medicinal products in Bulgaria
In August 2023, the Bulgarian Ministry of Health published a draft bill for amendment of the Law on Medicinal Products in the Human Medicine for public consultations. The proposed changes mark a shift towards greater transparency and regulatory control over the pharmaceutical value chain in Bulgaria. They target practices of parallel distributors which lead to […]...
Competition Breakfast: Overview of developments in antitrust law in the last year (Vienna)
What has happened in antitrust law in the last year? You get an overview. In particular, we report on the following: When & Where: Date: 17 January 2024Start: 08:30End: 10:30 Location: Schubertring 6, 1010 Vienna Competition Breakfast: Übersicht Entwicklungen im Kartellrecht im letzten Jahr Was hat sich getan im Kartellrecht im letzten Jahr. Sie erhalten […]...
Antitrust reform in Ukraine: The stage is set
In early September of this year, the President of Ukraine signed the Law “On Amendments to Certain Legislative Acts of Ukraine on Improving Legislation on Protection of Economic Competition and Activities of the Antimonopoly Committee of Ukraine” (the “Law”). The Law launches the reform of Ukrainian antitrust legislation which had been blocked by the Ukrainian […]...
Was bringt die BVergG Novelle 2024?
In dieser Folge unseres Vergaberecht-Podcasts diskutieren Johann Hwezda und Dominik König das Thema “ Was bringt die BVergG Novelle 2024?”. Sie diskutieren die bevorstehenden Änderungen durch die BVergG Novelle 2024, die die Änderungen in drei Hauptkategorien mit sich bringt: Klarstellungen zu vorhandenen Regelungen, Umsetzung der Judikatur und einige Neuerungen. Die Änderungen beziehen sich auf so […]...
Wishing you health, prosperity, and satisfaction in 2024
As 2023 comes to a close, Wolf Theiss expresses gratitude for the trust and collaboration received throughout the year. Despite global challenges, the successes shared with our valued clients and partners stand out. Looking towards 2024, our reflection on the past months reinforces our commitment to understanding unique challenges and offering tailored solutions. With our […]...
Employment Brief: Bulgaria to implement “the right to disconnect” and other changes for remote workers
Widely debated amendments in the Bulgarian Labour Code are expected to enter into force in early 2024, elaborating on remote/hybrid work provisions introduced in local legislation in 2011. A summary of some key changes from the legislative draft can be found below. Right to Disconnect The “right to disconnect” concept was developed at the EU […]...
Umsetzung der Work-Life-Balance-Richtlinie in Österreich (Teil 2)
In dieser Folge setzen Isabel Firneis und Julia Marboe die Diskussion über die Umsetzung der EU-Work-Life-Balance-Richtlinie in Österreich fort und knüpfen damit an die vorherige Folge des Arbeitsrecht-Podcasts an. Im Fokus dieser Folge stehen die neuen schriftlichen Begründungspflichten für Arbeitgeber, die Ausweitung des Motivkündigungsschutzes für Arbeitnehmer sowie die Erweiterung des Gleichbehandlungsgesetzes in Zusammenhang mit gewisse […]...
Renowned international arbitration and regulatory expert Marie Talašová joins Wolf Theiss
Prague, 7 December 2023 – Wolf Theiss appoints Marie Talašová to strengthen its Dispute Resolution team in Prague. Marie joins as Counsel, bringing with her 15 years of expertise in international arbitration. With the addition of another highly experienced counsel to its team, Wolf Theiss is primed for further strategic growth in 2024. Wolf Theiss […]...
Wolf Theiss advises QPS Holdings, LLC on the sale of its neuropharmacology business unit, QPS Neuropharmacology, to Scantox
Vienna, 06 December 2023 – Wolf Theiss advised leading drug development CRO (Contract Research Organization) QPS Holdings on the sale of 100% of the shares in its neuropharmacology business unit, QPS Neuropharmacology, to leading Nordic pre-clinical GLP-accredited CRO Scantox. Wolf Theiss advised QPS Holdings, LLC on all Austrian law aspects of this transaction including drafting […]...
Digital Services Act explained: New obligations for online businesses and other digital services
The EU Digital Services Act (DSA) has introduced a new liability and compliance framework for digital services offered to users within the European Union. While large platform providers like Meta or Amazon are already subject to the new rules since August 2023, the DSA’s comprehensive compliance obligations will become fully applicable to all covered online […]...
Wolf Theiss advises Kyoto Group on delivery of one of a kind Heat-as-a-Service (HaaS) to a major Hungarian food ingredient producer
Budapest, 04 December 2023 – Wolf Theiss Budapest has acted as lead legal counsel to Kyoto Group during the contractual phase of the project to deliver its Heatcube, a thermal energy storage system using molten salt and excess electricity, to Hungarian food ingredient producer KALL Ingredients Kft. Kyoto Group, together with its financial partner Kyotherm […]...
Arbeitsrecht rund um Weihnachten
Es ist wieder soweit: Lebkuchen, Adventskalender, Weihnachtsmärkte und Kollegen, die “Last Christmas” trällern. In dieser Folge sprechen Magdalena Ziembicka und Dorothea Arlt über arbeitsrechtliche Aspekte im Zusammenhang mit Weihnachten: vom Weihnachtsgeld über Dekoration am Arbeitsplatz und Betriebsfeiern bis hin zu Möglichkeiten, die freien Tage während der Festtage zu verlängern. Bei Fragen zu dieser Folge und […]...